249 related articles for article (PubMed ID: 27686810)
1. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
2. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
3. Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.
Masucci MT; Motti ML; Minopoli M; Di Carluccio G; Carriero MV
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37046997
[TBL] [Abstract][Full Text] [Related]
4. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
5. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
6. An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
Gheysen M; Vander Borght S; Lehnert S; Vanslembrouck R; Vanden Bempt I; Schöffski P
Oncol Res Treat; 2020; 43(9):470-473. PubMed ID: 32640452
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
[TBL] [Abstract][Full Text] [Related]
8. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
9. New treatments in advanced gastrointestinal stromal tumor.
Serrano C
Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479
[TBL] [Abstract][Full Text] [Related]
10. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
11. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
Schaefer IM; DeMatteo RP; Serrano C
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913
[TBL] [Abstract][Full Text] [Related]
12. KIT
Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
[TBL] [Abstract][Full Text] [Related]
13. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A; Rosell J; Sayols S; Gómez-Peregrina D; Pilco-Janeta DF; Olivares-Rivas I; de Álava E; Maurel J; Rubió-Casadevall J; Esteve A; Gut M; Valverde C; Barretina J; Carles J; Demetri GD; Fletcher JA; Arribas J; Serrano C
Oncogene; 2021 Dec; 40(48):6614-6626. PubMed ID: 34621020
[TBL] [Abstract][Full Text] [Related]
14. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Keretsu S; Ghosh S; Cho SJ
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146
[TBL] [Abstract][Full Text] [Related]
15. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
16. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.
Napolitano A; Thway K; Smith MJ; Huang PH; Jones RL
Chemotherapy; 2022; 67(2):81-90. PubMed ID: 34983047
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors: A multidisciplinary challenge.
Sanchez-Hidalgo JM; Duran-Martinez M; Molero-Payan R; Rufian-Peña S; Arjona-Sanchez A; Casado-Adam A; Cosano-Alvarez A; Briceño-Delgado J
World J Gastroenterol; 2018 May; 24(18):1925-1941. PubMed ID: 29760538
[TBL] [Abstract][Full Text] [Related]
18. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
Zhao Y; Weng Z; Zhou X; Xu Z; Cao B; Wang B; Li J
J Transl Med; 2023 Mar; 21(1):219. PubMed ID: 36966336
[TBL] [Abstract][Full Text] [Related]
20. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors.
Amirnasr A; Sleijfer S; Wiemer EAC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32972022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
